{"id":"https://openalex.org/W4380877495","doi":"https://doi.org/10.1186/s40814-023-01325-y","title":"Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity","display_name":"Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity","publication_year":2023,"publication_date":"2023-06-16","ids":{"openalex":"https://openalex.org/W4380877495","doi":"https://doi.org/10.1186/s40814-023-01325-y","pmid":"https://pubmed.ncbi.nlm.nih.gov/37328890","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/10273764"},"language":"en","primary_location":{"id":"doi:10.1186/s40814-023-01325-y","doi":"https://doi.org/10.1186/s40814-023-01325-y","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s40814-023-01325-y","pdf_url":"https://pilotfeasibilitystudies.biomedcentral.com/counter/pdf/10.1186/s40814-023-01325-y","source":{"id":"https://openalex.org/S2764511738","display_name":"Pilot and Feasibility Studies","issn_l":"2055-5784","issn":["2055-5784"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","norway-1","oarl","poland-20","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pilot and Feasibility Studies","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://pilotfeasibilitystudies.biomedcentral.com/counter/pdf/10.1186/s40814-023-01325-y","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5030286595","display_name":"Isabel H Gonzalez-Bocco","orcid":"https://orcid.org/0000-0002-2073-092X","observed_orcids":["https://orcid.org/0000-0002-2073-092X"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Isabel H. Gonzalez-Bocco","raw_affiliation_strings":["Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA. Isabel_gonzalez-bocco@dfci.harvard.edu","Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, MA, USA. Isabel_gonzalez-bocco@dfci.harvard.edu","Harvard Medical School, Boston, MA, USA. Isabel_gonzalez-bocco@dfci.harvard.edu","Division of Infectious Disease, Brigham and Women\u2019s Hospital, Boston, USA","Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, USA","Harvard Medical School, Boston, USA"],"raw_orcid":"https://orcid.org/0000-0002-2073-092X","affiliations":[{"raw_affiliation_string":"Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA. Isabel_gonzalez-bocco@dfci.harvard.edu","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, MA, USA. Isabel_gonzalez-bocco@dfci.harvard.edu","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Harvard Medical School, Boston, MA, USA. Isabel_gonzalez-bocco@dfci.harvard.edu","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Division of Infectious Disease, Brigham and Women\u2019s Hospital, Boston, USA","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, USA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Harvard Medical School, Boston, USA","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006024199","display_name":"Katherine Beluch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Katherine Beluch","raw_affiliation_strings":["Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA","Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, MA, USA","Division of Infectious Disease, Brigham and Women\u2019s Hospital, Boston, USA","Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Division of Infectious Disease, Brigham and Women\u2019s Hospital, Boston, USA","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033800251","display_name":"Alyssa Cho","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alyssa Cho","raw_affiliation_strings":["Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA","Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, MA, USA","Division of Infectious Disease, Brigham and Women\u2019s Hospital, Boston, USA","Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Division of Infectious Disease, Brigham and Women\u2019s Hospital, Boston, USA","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028552740","display_name":"Chlo\u00e9 Lahoud","orcid":"https://orcid.org/0000-0003-2346-8733","observed_orcids":["https://orcid.org/0000-0003-2346-8733"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chloe Lahoud","raw_affiliation_strings":["Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA","Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, MA, USA","Harvard Medical School, Boston, MA, USA","Division of Infectious Disease, Brigham and Women\u2019s Hospital, Boston, USA","Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, USA","Harvard Medical School, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Division of Infectious Disease, Brigham and Women\u2019s Hospital, Boston, USA","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, USA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Harvard Medical School, Boston, USA","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090462460","display_name":"Fabiola A. Reyes","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Fabiola A. Reyes","raw_affiliation_strings":["Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA","Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, MA, USA","Harvard Medical School, Boston, MA, USA","Division of Infectious Disease, Brigham and Women\u2019s Hospital, Boston, USA","Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, USA","Harvard Medical School, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Division of Infectious Disease, Brigham and Women\u2019s Hospital, Boston, USA","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, USA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Harvard Medical School, Boston, USA","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083634231","display_name":"Dimitrios G Moshovitis","orcid":"https://orcid.org/0009-0007-1337-8984","observed_orcids":["https://orcid.org/0009-0007-1337-8984"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dimitrios G. Moshovitis","raw_affiliation_strings":["Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA","Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, MA, USA","Division of Infectious Disease, Brigham and Women\u2019s Hospital, Boston, USA","Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Division of Infectious Disease, Brigham and Women\u2019s Hospital, Boston, USA","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040299524","display_name":"Gillian M. Unger-Mochrie","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gillian M. Unger-Mochrie","raw_affiliation_strings":["Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA","Division of Infectious Disease, Brigham and Women\u2019s Hospital, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"Division of Infectious Disease, Brigham and Women\u2019s Hospital, Boston, USA","institution_ids":["https://openalex.org/I1283280774"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108048776","display_name":"Wei Wang","orcid":"https://orcid.org/0000-0002-3827-0474","observed_orcids":["https://orcid.org/0000-0002-3827-0474"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wei Wang","raw_affiliation_strings":["Harvard Medical School, Boston, MA, USA","Medicine Department, Brigham and Women's Hospital, Boston, MA, USA","Harvard Medical School, Boston, USA","Medicine Department, Brigham and Women\u2019s Hospital, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Medicine Department, Brigham and Women's Hospital, Boston, MA, USA","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"Harvard Medical School, Boston, USA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Medicine Department, Brigham and Women\u2019s Hospital, Boston, USA","institution_ids":["https://openalex.org/I1283280774"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036680177","display_name":"Sarah Page Hammond","orcid":"https://orcid.org/0000-0002-4271-7443","observed_orcids":["https://orcid.org/0000-0002-4271-7443"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah P. Hammond","raw_affiliation_strings":["Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, MA, USA","Division of Infectious Disease, Massachusetts General Hospital, Boston, MA, USA","Harvard Medical School, Boston, MA, USA","Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, USA","Division of Infectious Disease, Massachusetts General Hospital, Boston, USA","Harvard Medical School, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Division of Infectious Disease, Massachusetts General Hospital, Boston, MA, USA","institution_ids":["https://openalex.org/I4210087915"]},{"raw_affiliation_string":"Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, USA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Division of Infectious Disease, Massachusetts General Hospital, Boston, USA","institution_ids":["https://openalex.org/I4210087915"]},{"raw_affiliation_string":"Harvard Medical School, Boston, USA","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057245327","display_name":"Jennifer Manne\u2010Goehler","orcid":"https://orcid.org/0000-0001-9295-0035","observed_orcids":["https://orcid.org/0000-0001-9295-0035"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Manne-Goehler","raw_affiliation_strings":["Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA","Division of Infectious Disease, Massachusetts General Hospital, Boston, MA, USA","Harvard Medical School, Boston, MA, USA","Division of Infectious Disease, Brigham and Women\u2019s Hospital, Boston, USA","Division of Infectious Disease, Massachusetts General Hospital, Boston, USA","Harvard Medical School, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"Division of Infectious Disease, Massachusetts General Hospital, Boston, MA, USA","institution_ids":["https://openalex.org/I4210087915"]},{"raw_affiliation_string":"Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Division of Infectious Disease, Brigham and Women\u2019s Hospital, Boston, USA","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"Division of Infectious Disease, Massachusetts General Hospital, Boston, USA","institution_ids":["https://openalex.org/I4210087915"]},{"raw_affiliation_string":"Harvard Medical School, Boston, USA","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5042918956","display_name":"Sophia Koo","orcid":"https://orcid.org/0000-0002-4973-7439","observed_orcids":["https://orcid.org/0000-0002-4973-7439"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Sophia Koo","raw_affiliation_strings":["Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA. skoo@bwh.harvard.edu","Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, MA, USA. skoo@bwh.harvard.edu","Harvard Medical School, Boston, MA, USA. skoo@bwh.harvard.edu","Division of Infectious Disease, Brigham and Women\u2019s Hospital, Boston, USA","Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, USA","Harvard Medical School, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA. skoo@bwh.harvard.edu","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, MA, USA. skoo@bwh.harvard.edu","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Harvard Medical School, Boston, MA, USA. skoo@bwh.harvard.edu","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Division of Infectious Disease, Brigham and Women\u2019s Hospital, Boston, USA","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, USA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Harvard Medical School, Boston, USA","institution_ids":["https://openalex.org/I136199984"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5030286595","https://openalex.org/A5042918956"],"corresponding_institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984","https://openalex.org/I4210117453"],"apc_list":{"value":2290,"currency":"USD","value_usd":2290},"apc_paid":{"value":2290,"currency":"USD","value_usd":2290},"fwci":1.6466,"has_fulltext":true,"cited_by_count":8,"citation_normalized_percentile":{"value":0.82448496,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"9","issue":"1","first_page":"100","last_page":"100"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10118","display_name":"SARS-CoV-2 and COVID-19 Research","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10118","display_name":"SARS-CoV-2 and COVID-19 Research","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10041","display_name":"COVID-19 Clinical Research Studies","score":0.0027000000700354576,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sotrovimab","display_name":"sotrovimab","score":0.9049999713897705},{"id":"https://openalex.org/keywords/covid-19-prevention","display_name":"COVID-19 prevention","score":0.9440000057220459},{"id":"https://openalex.org/keywords/pre-exposure-prophylaxis","display_name":"pre-exposure prophylaxis","score":0.9470000267028809},{"id":"https://openalex.org/keywords/immunocompromised-patients","display_name":"immunocompromised patients","score":0.871999979019165},{"id":"https://openalex.org/keywords/sars-cov-2-spike-antibodies","display_name":"SARS-CoV-2 spike protein antibodies","score":0.8149999976158142},{"id":"https://openalex.org/keywords/dosing-interval","display_name":"dosing interval","score":0.6669999957084656},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.902999997138977},{"id":"https://openalex.org/keywords/infusion-related-reactions","display_name":"infusion reactions","score":0.9279999732971191},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8830000162124634},{"id":"https://openalex.org/keywords/post-marketing-surveillance","display_name":"post-marketing surveillance","score":0.3440000116825104}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8924444913864136},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7401354312896729},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.7148393392562866},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.6452903747558594},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5958797931671143},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.5757681131362915},{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.5129544138908386},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.4565240740776062},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.45455634593963623},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.44485539197921753},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4224681258201599},{"id":"https://openalex.org/C201903717","wikidata":"https://www.wikidata.org/wiki/Q1778788","display_name":"Cohort study","level":2,"score":0.4177089035511017},{"id":"https://openalex.org/C22070199","wikidata":"https://www.wikidata.org/wiki/Q192995","display_name":"Vaccination","level":2,"score":0.4175901412963867},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4137445390224457},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.34055203199386597},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.33812132477760315},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":5,"locations":[{"id":"doi:10.1186/s40814-023-01325-y","doi":"https://doi.org/10.1186/s40814-023-01325-y","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s40814-023-01325-y","pdf_url":"https://pilotfeasibilitystudies.biomedcentral.com/counter/pdf/10.1186/s40814-023-01325-y","source":{"id":"https://openalex.org/S2764511738","display_name":"Pilot and Feasibility Studies","issn_l":"2055-5784","issn":["2055-5784"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","norway-1","oarl","poland-20","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pilot and Feasibility Studies","raw_type":"journal-article"},{"id":"doi:10.21203/rs.3.rs-1821159/v1","doi":"https://doi.org/10.21203/rs.3.rs-1821159/v1","is_oa":true,"landing_page_url":"https://doi.org/10.21203/rs.3.rs-1821159/v1","pdf_url":"https://www.researchsquare.com/article/rs-1821159/latest.pdf","source":{"id":"https://openalex.org/S4306525896","display_name":"Research Square","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Research Square","raw_type":"posted-content"},{"id":"pmh:oai:pubmedcentral.nih.gov:10273764","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10273764","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10273764/pdf/40814_2023_Article_1325.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pilot Feasibility Stud","raw_type":"Text"},{"id":"pmid:37328890","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37328890","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pilot and feasibility studies","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:ad657617d462466bb5be8c3ad95de933","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/ad657617d462466bb5be8c3ad95de933","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Pilot and Feasibility Studies, Vol 9, Iss 1, Pp 1-10 (2023)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1186/s40814-023-01325-y","doi":"https://doi.org/10.1186/s40814-023-01325-y","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s40814-023-01325-y","pdf_url":"https://pilotfeasibilitystudies.biomedcentral.com/counter/pdf/10.1186/s40814-023-01325-y","source":{"id":"https://openalex.org/S2764511738","display_name":"Pilot and Feasibility Studies","issn_l":"2055-5784","issn":["2055-5784"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","norway-1","oarl","poland-20","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pilot and Feasibility Studies","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/study-protocol","display_name":"Study Protocol"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307773","display_name":"GlaxoSmithKline","ror":"https://ror.org/01xsqw823"},{"id":"https://openalex.org/F4320319159","display_name":"Vir Biotechnology","ror":"https://ror.org/030pjfg04"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4380877495.pdf","grobid_xml":"https://content.openalex.org/works/W4380877495.grobid-xml"},"referenced_works_count":38,"referenced_works":["https://openalex.org/W2169852145","https://openalex.org/W2328527542","https://openalex.org/W2607120647","https://openalex.org/W2943418339","https://openalex.org/W2946337557","https://openalex.org/W3012310845","https://openalex.org/W3025232799","https://openalex.org/W3046463683","https://openalex.org/W3097738396","https://openalex.org/W3102798166","https://openalex.org/W3118873013","https://openalex.org/W3123551159","https://openalex.org/W3135758766","https://openalex.org/W3143907823","https://openalex.org/W3154813174","https://openalex.org/W3156866359","https://openalex.org/W3158103490","https://openalex.org/W3159265369","https://openalex.org/W3164409248","https://openalex.org/W3164747805","https://openalex.org/W3165032628","https://openalex.org/W3168511545","https://openalex.org/W3172958999","https://openalex.org/W3174178131","https://openalex.org/W3174588189","https://openalex.org/W3174790825","https://openalex.org/W3175562186","https://openalex.org/W3176897911","https://openalex.org/W3184620427","https://openalex.org/W3187717873","https://openalex.org/W3190427561","https://openalex.org/W3191062648","https://openalex.org/W3193104554","https://openalex.org/W3194536759","https://openalex.org/W3199126560","https://openalex.org/W3205716711","https://openalex.org/W3208080692","https://openalex.org/W4310030105"],"related_works":["https://openalex.org/W4413136356","https://openalex.org/W4389031413","https://openalex.org/W4317743384","https://openalex.org/W4306672755","https://openalex.org/W7122829242","https://openalex.org/W4311607010","https://openalex.org/W4416599723","https://openalex.org/W4281663367","https://openalex.org/W4387981894","https://openalex.org/W4400701323"],"abstract_inverted_index":{"BACKGROUND:":[0],"Multiple":[1],"vaccines":[2],"have":[3],"been":[4],"approved":[5],"since":[6],"August":[7],"2021":[8],"to":[9,20,72,149,161,164,293,313],"prevent":[10],"infection":[11,34],"with":[12,74,122,171,300],"SARS-CoV-2;":[13],"however,":[14],"20-40%":[15],"of":[16,33,95,167,189,194,207,226,230,268,285,324],"immunocompromised":[17,101,120,291,298],"people":[18],"fail":[19],"develop":[21],"SARS-CoV-2":[22,56,130,302],"spike":[23,57,131],"antibodies":[24],"after":[25,246],"COVID-19":[26,241,315],"vaccination":[27],"and":[28,35,69,92,108,192,240,305,321],"remain":[29],"at":[30],"high":[31],"risk":[32],"more":[36],"severe":[37],"illness":[38],"than":[39],"non-immunocompromised":[40],"hosts.":[41],"Sotrovimab":[42],"(VIR-7831)":[43],"is":[44,60],"a":[45,51,123,143,172,217,252],"monoclonal":[46],"neutralizing":[47],"antibody":[48],"that":[49,221],"binds":[50],"conserved":[52],"epitope":[53],"on":[54,209],"the":[55,89,136,151,190,199,210,224,231,247,266,318,328],"protein.":[58],"It":[59],"neither":[61],"renally":[62],"excreted":[63],"nor":[64],"metabolized":[65],"by":[66],"P450":[67],"enzymes":[68],"therefore":[70],"unlikely":[71],"interact":[73],"concomitant":[75],"medications":[76],"(e.g.,":[77],"immunosuppressive":[78],"medications).":[79],"In":[80,133,196,251],"this":[81,111,159],"open-label":[82,281],"feasibility":[83,282],"study":[84,148,283,319],"protocol,":[85],"we":[86,278],"will":[87,116,140,157,181,215,222,235],"define":[88,306],"optimal":[90,152,307],"dose":[91],"dosing":[93,153,308],"interval":[94],"sotrovimab":[96,176,208,212,274,286],"as":[97,103,105,287],"pre-exposure":[98,288],"prophylaxis":[99,289],"for":[100,186,238,243,290],"individuals":[102,292,299],"well":[104],"its":[106,295],"safety":[107,191,219,239],"tolerability":[109,193],"in":[110,142,265,271,297],"population":[112,160],"specifically.":[113],"METHODS:":[114],"We":[115,310],"enroll":[117],"93":[118],"eligible":[119],"adults":[121],"negative":[124],"or":[125],"low-positive":[126],"(<":[127],"50":[128,162],"U/mL)":[129],"antibody.":[132],"phase":[134,197,254],"1,":[135],"first":[137,200],"10":[138,201],"patients":[139,202,234,272],"participate":[141],"lead-in":[144,218],"pharmacokinetics":[145],"(PK)":[146],"cohort":[147,185,220],"determine":[150,314],"interval.":[154],"Phase":[155,179],"2":[156],"expand":[158],"participants":[163],"examine":[165],"rates":[166],"infusion-related":[168],"reactions":[169],"(IRR)":[170],"30-min":[173],"500":[174],"mg":[175,205],"IV":[177,206],"infusion.":[178],"3":[180],"be":[182,236],"an":[183,280],"expansion":[184],"further":[187],"assessment":[188],"sotrovimab.":[195],"4,":[198],"receiving":[203,273],"2000":[204],"second":[211,248],"infusion":[213],"day":[214],"comprise":[216],"inform":[223],"duration":[225],"observation":[227],"following":[228],"administration":[229],"drug.":[232],"The":[233],"followed":[237],"events":[242,270],"36":[244],"weeks":[245],"dose.":[249],"DISCUSSION:":[250],"previous":[253],"III":[255],"randomized,":[256],"placebo-controlled":[257],"pivotal":[258],"trial,":[259],"there":[260],"were":[261],"no":[262],"significant":[263],"differences":[264],"prevalence":[267],"adverse":[269],"vs.":[275],"placebo.":[276],"Thus,":[277],"propose":[279],"protocol":[284],"evaluate":[294],"PK":[296],"impaired":[301],"humoral":[303],"immunity":[304],"intervals.":[309],"also":[311],"aim":[312],"infections":[316],"over":[317],"period":[320],"self-reported":[322],"quality":[323],"life":[325],"measures":[326],"throughout":[327],"study.":[329],"TRIAL":[330],"REGISTRATION:":[331],"ClinicalTrials.gov":[332],"Identifier:":[333],"NCT05210101.":[334]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":2}],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2023-06-17T00:00:00"}